Patients with type 2 diabetes who achieve reduced postprandial glucose levels during insulin intensive therapy may have a better recovery of β-cell function
An erratum to this article was published (Diabetes Res Clin Pract, Nov 2025 ↗)
Authors' conclusion
Drug-naïve T2D patients with lower postprandial glucose concentration during CSII therapy exhibit better β-cell function recovery.
Study context
- Population
- Drug-naïve patients with T2D receiving continuous subcutaneous insulin infusion (CSII) therapy, hospitalized
- Participants
- 99 patients
- Comparison
- Metformin add-on NovoRapid vs Prandilin during CSII
- Primary endpoint
- Factors contributing to better β-cell function recovery after CSII therapy
Methodological detailsinpatient, Lead-in period, 4-day CGM period, 2-3 weeks treatment period; OGTTs at baseline and endpoint
- Inpatient
- Lead-in period, 4-day CGM period, 2-3 weeks treatment period; OGTTs at baseline and endpoint
Primary result
As reported in the abstract
Factors of β-cell function recovery after CSII · endpoint
Improvement in C-peptide levels
83
84 %
No change in C-peptide levels
16
16 %
Correlation of incremental AUC of glucose (0700 to 1000) with increase in incremental AUC of C-peptide (Pearson)
r = −0.199
P < 0.05
Further findings
Time to glycemic control
- Glycemic control achieved within (days)
- 3.8 ± 1.1
Original publication
Patients with type 2 diabetes who achieve reduced postprandial glucose levels during insulin intensive therapy may have a better recovery of β-cell function. Diabetes Res Clin Pract. Published 3 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →